Brokerages expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report $10.20 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $9.58 million and the highest is $10.82 million. BioCryst Pharmaceuticals reported sales of $9.44 million during the same quarter last year, which would suggest a positive year over year growth rate of 8.1%. The business is expected to report its next earnings report on Thursday, May 3rd.
On average, analysts expect that BioCryst Pharmaceuticals will report full year sales of $10.20 million for the current fiscal year, with estimates ranging from $6.00 million to $28.61 million. For the next year, analysts forecast that the firm will post sales of $24.60 million per share, with estimates ranging from $23.02 million to $26.18 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.06). The business had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $6.07 million. BioCryst Pharmaceuticals had a negative return on equity of 106.53% and a negative net margin of 261.18%. The business’s quarterly revenue was down 56.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.06) earnings per share.
BCRX has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. Barclays assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 target price on the stock. BidaskClub raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research note on Tuesday, January 2nd. Finally, Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.29.
A number of hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its stake in BioCryst Pharmaceuticals by 6.4% during the second quarter. The Manufacturers Life Insurance Company now owns 63,116 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 3,774 shares during the period. Voya Investment Management LLC increased its position in shares of BioCryst Pharmaceuticals by 12.1% during the second quarter. Voya Investment Management LLC now owns 38,275 shares of the biotechnology company’s stock valued at $213,000 after acquiring an additional 4,127 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 4.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock valued at $1,678,000 after acquiring an additional 12,267 shares during the last quarter. American International Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 22.9% during the fourth quarter. American International Group Inc. now owns 66,002 shares of the biotechnology company’s stock valued at $324,000 after acquiring an additional 12,317 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 183,643 shares of the biotechnology company’s stock valued at $901,000 after acquiring an additional 13,306 shares during the last quarter. 91.54% of the stock is currently owned by institutional investors.
BCRX stock traded up $0.23 during trading hours on Friday, hitting $5.27. 697,334 shares of the stock traded hands, compared to its average volume of 1,268,508. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $504.86, a P/E ratio of -6.76 and a beta of 2.63. BioCryst Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $8.99.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.